Human IL-15 Protein, Tag Free (SPR verified)
Proteins and Peptides
- 貨號 Cat. No.
- IL5-H4117
- 規格 Size
- 50ug
- 品牌 Brand
- ACROBiosystems
- Species
- Human
- Conjugate
- Unconjugated
- Expression System
- E. coli
- Tag
- Tag Free
Description
Source :
Human IL-15, Tag Free (IL5-H4117) is expressed from E.coli cells. It contains AA Asn 49 - Ser 162 (Accession # P40933-1).
Molecule : IL-15
Synonyms : IL-15,Interleukin-15,MGC9721
Format : Powder
Category : Cytokines&Growth Factors
Accession : AAH18149.1
Storage : -20℃
Shipping condition : Powder,RT
Molecular Weight : 12.8 kDa
Characteristics :
This protein carries no "tag". The protein has a calculated MW of 12.8 kDa. The protein migrates as 13 kDa under reducing (R) condition (SDS-PAGE).
Endotoxin Level : Less than 0.1 EU per μg by the LAL method.
Buffer : PBS, pH7.4
Description :
Interleukin 15 is also known as IL15, IL-15, and is a cytokine with structural similarity to IL-2. Like IL-2, IL-15 binds to and signals through the IL-2/IL-15 beta chain (CD122) and the common gamma chain (gamma-C, CD132). IL-15 is secreted by mononuclear phagocytes (and some other cells) following infection by virus(es). This cytokine induces cell proliferation of natural killer cells; cells of the innate immune system whose principal role is to kill virally infected cells. Interleukin 15 (IL-15) regulates T and natural killer (NK) cell activation and proliferation. Survival signals that maintain memory T cells in the absence of antigen are provided by IL-15. This cytokine is also implicated in NK cell development. In rodent lymphocytes, IL-15 prevents apoptosis by inducing an apoptosis inhibitor, BCL2L1/BCL-x(L). IL-15 has been shown to enhance the anti-tumor immunity of CD8+ T cells in pre-clinical models. A phase I clinical trial to evaluate the safety, dosing, and anti-tumor efficacy of IL-15 in patients with metastatic melanoma and renal cell carcinoma (kidney cancer) has begun to enroll patients at the National Institutes of Health.
References :
(1) Grabstein KH, et al. 1994, Science 264 (5161): 965–8.
(2) Malamut G, et al. 2010, J. Clin. Invest. 120 (6): 2131–43.
(3) Klebanoff CA, et al. 2004, Proc. Natl. Acad. Sci. U.S.A. 101 (7): 1969–74.
(4) Teague RM, et al. 2006, Nat. Med. 12 (3): 335–41.

